TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03546946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-Contingent Music Reward Training
Description: Participants will hear their selected music track playing, dependent on their gaze location, when viewing a grid on neutral and negative faces.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Training
Description: Participants will hear their selected music track playing, regardless of their gaze location, when viewing a grid on neutral and negative faces.
Study: NCT00808600

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensified anaerobic exercise training
Description: Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate aerobic exercise training
Description: Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate aerobic exercise training
Description: Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
Study: NCT05416034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the ATLAS 2025 exoskeleton at home
Description: Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
Study: NCT00730366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine
Description: Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine
Description: Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
Study: NCT03638648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
Study: NCT04516291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Study: NCT02553421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400
Description: The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400
Description: The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400
Description: The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
Study: NCT00352612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin
Description: clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
Study: NCT00990743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL040012
Description: Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
Study: NCT00550017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epofolate
Description: Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
Study: NCT00530738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplus
Description: i.v. fat emulsion for parenteral nutrition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin MCT
Description: i.V. fat emulsion for parenteral nutrition
Study: NCT04783909

Intervention type: PROCEDURE
Intervention: Phacoemulsification cataract surgery
Description: All surgeries were performed using Infinity (Alcon Laboratories, Inc.) under topical anaesthesia by one surgeon through 2.2 mm incision in the upper corneal limbus. The hydroimplantation of IOL to the capsular bag was performed in all cases.
Study: NCT04516291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Study: NCT00352612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cephalexin
Description: cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
Study: NCT02827292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No music
Description: Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: Patients will undergo Laparoscopic Surgery as per the set protocol
Study: NCT00369577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled Placebo, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 5 mg
Description: Inhaled Staccato Loxapine 5 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 10 mg
Description: Inhaled Staccato Loxapine 10 mg, single dose
Study: NCT00684775

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Work Plus Naltrexone Contingency
Description: Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month.
Study: NCT01391663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
Study: NCT04516291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Study: NCT01278823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic roux en y gastric bypass operation
Description: roux en y gastric bypass operation
Study: NCT02827292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: Patients will undergo Laparoscopic Surgery as per the set protocol
Study: NCT02259491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka Honey Dressing
Description: After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
Study: NCT03077165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 100 mg
Description: 50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 200 mg
Description: 50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study: NCT01278823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical management
Description: latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
Study: NCT01238861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 2 mg
Description: EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
Study: NCT03077165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 400 mg
Description: 200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 800 mg
Description: 200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 1200 mg
Description: 200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
Study: NCT01238861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 20 mg
Description: EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Description: EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Description: EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: EOS+ and EOS- participants received two placebo injections subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: EOS+ and EOS- participants received two placebo injections subcutaneously.
Study: NCT02970838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured weight-loss program
Description: During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling.
Study: NCT03126097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64155806 150 mg
Description: JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/drospirenone 0.02 mg/3 mg
Description: Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COCP Placebo
Description: Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
Study: NCT01932541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latuda (Lurasidone)
Description: Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
Study: NCT01753570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV(24 weeks)
Description: RBV: 600 - 1000mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN beta(24 weeks)
Description: IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
Study: NCT01391663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
Study: NCT03923894

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Yeast Fermentation Freeze Dying Powder Extract
Description: Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.07 g/day for 8 weeks.
Study: NCT04311684

Intervention type: DEVICE
Intervention: hybrid Brillouin-Raman spectroscopy
Description: Combination of Brillouin and surface-enhanced Raman (SERS) spectroscopy for assessment of both visco-elastic (i.e. mechanical) and chemical characterization of urinary proteins at the same time from the same excitation laser source

Intervention type: DEVICE
Intervention: hybrid Brillouin-Raman spectroscopy
Description: Combination of Brillouin and surface-enhanced Raman (SERS) spectroscopy for assessment of both visco-elastic (i.e. mechanical) and chemical characterization of urinary proteins at the same time from the same excitation laser source
Study: NCT03946163

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cinnamon capsules
Description: each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
Study: NCT03410225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMI-TPP
Description: The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAMI-Fitness
Description: The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
Study: NCT00745914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator
Study: NCT00808769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zegerid®
Description: capsule(20 mg omeprazole/sodium bicarbonate), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec OTC®
Description: Omeprazole-magnesium 20.6 mg, tablet, single dose
Study: NCT01076140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
Study: NCT01846039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinked hyaluronic acid gel
Description: Up to 3 mL administered by intradermal injection
Study: NCT01433029

Intervention type: OTHER
Intervention: Surgical Video Assessments
Description: Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.

Intervention type: OTHER
Intervention: Surgical Video Assessments
Description: Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.

Intervention type: OTHER
Intervention: Video Recording of CAB
Description: Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
Study: NCT06335394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NVD003
Description: Autologous osteogenic implant NVD-003 for bone reconstruction
Study: NCT04882956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection
Description: Brolucizumab-Dbll intravitreal injection
Study: NCT05045339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ball Exercises
Description: Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed. Exercises were performed with 55 and 65 inch gym ball and a small regular plastic ball.
Study: NCT04760639

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Participants provide a breath sample
Study: NCT03225313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.5% Injection Solution_#4
Description: ultra sound guided injection into the rectus sheath

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution_#5
Description: injected into rectus sheath using ultrasound \& locally surrounding the hernia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 0.5% Injection Solution_#4
Description: locally surrounding the hernia
Study: NCT01682681

Intervention type: DRUG
Intervention: Topiramate
Description: This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
Study: NCT02231606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Glasses
Description: Provide free glasses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Glasses
Description: Provide free glasses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Glasses
Description: Provide free glasses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upgrade Glasses 1
Description: Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upgrade Glasses 2
Description: Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)